查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球化疗引起的贫血市场 - 2023-2030年
市场调查报告书
商品编码
1290353

全球化疗引起的贫血市场 - 2023-2030年

Global Chemotherapy-Induced Anemia Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球化疗诱导性贫血市场规模在2022年达到22.4亿美元，预计到2030年将见证有利可图的增长，达到38.935亿美元。在预测期间（2023-2030年），化疗引起的贫血市场预计将呈现7.2%的年增长率。

贫血是一种身体的红血球状态低于正常的情况。当身体不包含足够的红细胞时，身体各部分不能获得足够的氧气。因此，它们不能以它们需要的方式执行，并诱发问题。如果个人的身体不能产生足够的红细胞或将其消除，就会孕育出贫血。因此，如果个人从血液中流失过多的血液，甚至会诱发贫血。贫血是癌症和癌症治疗的一个典型副作用，对于接受化疗的人来说尤其如此。

市场动态

不断增长的癌症病例正在推动预测期内的全球化疗诱导性贫血市场。

在预测期内，不断增长的癌症病例正在推动全球化疗诱导性贫血市场的发展。例如，根据2022年发表的一项研究报告，在GLOBOCAN 2020中登记的癌症病例估计有1930万，死亡人数超过1000万。在这些患者中，全球典型检测出的癌症的发病率是女性前列腺癌（141万，7.3%）、肺癌（221万，11.4%）和乳腺癌（226万例，11.7%）。

老年人口为全球化疗诱发性贫血市场提供了前瞻性的增长机会。

癌症可以在任何年龄段生长，尽管随着个人年龄的增长，大多数种类的癌症变得更加典型。这是因为身体的细胞会在这段时间内受到伤害。这种恶化会随着个人年龄的增长而产生，并会经常产生癌症。因此，不断增长的老年人口为全球市场提供了在未来几年的增长机会。例如，根据联合国发布的《2022年世界人口前景》，80岁或以上的人的数量预计将增长三倍，从2022年的1.57亿增加到2050年的4.59亿。

COVID-19影响分析

COVID-19分析包括COVID前情景、COVID情景和COVID后情景以及定价动态（包括大流行期间和之后的定价变化与COVID前情景的比较）、需求-供应谱（由于贸易限制、封锁和后续问题造成的需求和供应变化）、政府倡议（政府机构为振兴市场、部门或行业采取的倡议）和制造商战略倡议（这里将涉及制造商为缓解COVID问题所做的工作）。

俄乌战争影响分析

由于乌克兰的战争造成了混乱，使数百万人背井离乡，许多乌克兰人不得不逃到国家的西部地区，成为欧洲和国外的难民。其中有癌症患者，他们遇到了极端疾病和流亡的猛烈一击。而在乌克兰的癌症医院被遗弃甚至被攻击的同时，乌克兰的病人在边界对面，受到制裁和通货膨胀的打击，甚至遇到了一个不确定的未来，他们的护理。

全球经济衰退影响分析

医疗保健行业并非完全不受经济衰退的影响，因为医疗机构在过去的金融衰退期间认为解雇和就业。尽管如此，由于其基本性质，该行业确实比其他行业应对得更好。然而，随着通货膨胀的持续增加，衰退的危险威胁着市场。由于全球发达国家的高通货膨胀率，对持续衰退的紧张程度上升，在过去两年中出现了普遍的成本激增。累积恶化的一般购买控制预计将特别影响增长中的经济体，并被认为在许多方面有帮助。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按疾病类型分析
  • 按治疗类型简述
  • 按药物类型分类
  • 按终端用户分类
  • 按地区分类

第4章：动态变化

  • 影响因素
    • 驱动因素
      • 研究活动
      • 癌症发病率的增长
    • 限制因素
      • 严格的监管机构
    • 机会
    • 政府倡议
    • 影响分析

第五章：行业分析

  • 波特的五力分析
  • 监管分析
  • 价格分析
  • 专利分析
  • PEST分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第7章 ：俄罗斯-乌克兰战争分析

第八章：全球经济衰退分析

第九章：按疾病类型

  • 轻度贫血
  • 中度贫血
  • 严重贫血

第十章：按治疗类型分类

  • 红细胞输注
  • 红细胞刺激剂（ESAs）。
  • 铁剂补充

第十一章：按药物类型分类

  • 伊波金注射液
  • 普罗克雷特注射液
  • Androxy口服液
  • Aranesp注射液
  • 注射用赤霉素Alfa
  • 其他

第十二章：按终端用户分类

  • 医院
  • 专业诊所
  • 非住院手术中心
  • 癌症研究中心
  • 癌症康复中心

第13章 ：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第十四章：竞争格局

  • 竞争格局
  • 市场份额分析
  • 合併和收购分析

第十五章 ：公司简介

  • Dr. Reddy's Laboratories Ltd.
    • 公司概述
    • 疾病类型组合和描述
    • 财务概况
    • 主要发展情况
  • Pfizer Inc
  • Panacea Biotec Limited
  • SBI PHARMACEUTICALS CO., LTD
  • Tolero Pharmaceuticals, Inc.
  • Vifor Pharma AG
  • Therapure Biopharma Inc.
  • PharmaEssentia Corp.
  • PhytoHealth Corp
  • UBI Pharma Inc

第16章 ：附录

简介目录
Product Code: PH1420

Market Overview

The Global Chemotherapy-Induced Anemia Market size reached USD 2,240 million in 2022 and is projected to witness lucrative growth by reaching up to USD 3,893.5 million by 2030. The chemotherapy-induced anemia market is expected to exhibit a cagr of 7.2% during the forecast period (2023-2030).

Anemia is a condition in which the body's status of red blood cells goes below normal. When the body does not contain adequate RBCs, the body parts do not acquire sufficient oxygen. As a consequence, they cannot perform in the manner they require to and induce issues. Individuals conceive anemia if their body does not produce adequate RBCs or eliminates them. Thus, individuals can even induce anemia if they lose too much blood from their bloodstream. Anemia is a typical side consequence of cancer and cancer therapy, specifically true for individuals accepting chemotherapy.

Market Dynamics

The Growing Cases Of Cancer Are Driving The Global Chemotherapy-Induced Anemia Market In The Forecast Period.

The growing cases of cancer are driving the global chemotherapy-induced anemia market during the forecast period. For instance, according to a research study published in 2022 worldwide, an assessed 19.3 million cases and over 10 million demises were because of cancer as registered in GLOBOCAN 2020. Among these entire patients, the incidence of typically detected cancers globally were female prostate cancers (1.41 million, 7.3%), lung (2.21 million, 11.4%), and breast (2.26 million cases, 11.7%).

The Geriatric Population Is Providing The Global Chemotherapy-Induced Anemia Market With Prospective Growth Opportunities.

Cancer can grow at any age, despite as individuals get older, a majority of kinds of cancer become more typical. This is because the body's cells can get harmed over the period. This deterioration can then produce up as individual ages, and can frequently yield cancer. Thus, the growing geriatric population presents the global market with prospective growth opportunities in the upcoming years. For instance, according to the World Population Prospects 2022, from the UN, the number of individuals aged 80 or above is anticipated to grow triple fold, from 157 million in 2022 to 459 million by 2050.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine War Impact Analysis

As the warfare in Ukraine released disorder and uprooted millions of individuals, numerous Ukrainians had to escape to the western region of the nation and became refugees in Europe and outside. Among them were individuals with cancer, who encountered a fierce one-two force of extreme sickness and exile. And while cancer hospitals in Ukraine are being deserted or even attacked, Ukrainian patients across the boundary, struck by sanctions and inflation, even encounter an indefinite future for their care.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employment during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession as the high inflation in developed countries worldwide has transpired in a general cost surge over the past two years. The cumulatively deteriorating general purchasing control is anticipated to affect growing economies particularly and is considered helpful in numerous ways.

Segment Analysis

The global chemotherapy-induced anemia market is segmented based on disease type, treatment type, drug type, end-user, and region.

The Erythropoiesis-Stimulating Agents (ESAs) Treatment Type Segment Is Estimated To Hold A 34.1% Share Of The Global Market By 2030.

The erythropoiesis-stimulating agents (ESAs) treatment type segment is estimated to hold about 34% of the total chemotherapy-induced anemia market by 2030, owing to the increasing clinical research activities. For instance, in May 2023, FibroGen, Inc., a top biopharmaceutical enterprise committed to finding, creating, and selling a product line of first-in-class therapeutics, and its associate, FibroGen (China) Medical Technology Development Co., Ltd. informed favorable topline information from corporation's Phase 3 clinical trial of roxadustat for the treatment of anemia in people taking coexisting chemotherapy drug for non-myeloid malignancies in China.

Geographical Analysis

Europe is Estimated To Hold The Second-Largest Share Of The Global Chemotherapy-Induced Anemia Market During The Forecast Period.

Owing to the growing number of cancer deaṭhs and measures to battle against cancer, Europe is estimated to hold about 26.6% of the global chemotherapy-induced anemia market by 2030. For instance, according to the 2022 edition of Health at a Glance, cancer is the second largest basis for death in the European Union following cardiovascular conditions. Over 30-50% of cancer individuals' deaths are avertable, and mortality can also be lowered via premature identification and the essential better punctual, and efficacious cures. Europe's Beating Cancer Plan aims to lower the burden of cancer and handle cancer-related inequalities among and in the governments, with struggles to aid, harmonize and satisfy the activities of Member States.

Competitive Landscape

The major global players in the market include: Dr. Reddy's Laboratories Ltd, Pfizer Inc, Panacea Biotec Limited, SBI PHARMACEUTICALS CO., LTD, Tolero Pharmaceuticals, Inc., Vifor Pharma AG, Therapure Biopharma Inc., PharmaEssentia Corp., PhytoHealth Corp, and UBI Pharma Inc among others.

Why Purchase the Report?

  • To visualize the global chemotherapy-induced anemia market segmentation based on disease type, treatment type, drug type, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of chemotherapy-induced anemia market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global chemotherapy-induced anemia market report would provide approximately 53 tables, 54 figures, and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by Drug Type
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Research Activities
      • 4.1.1.2. Growing Cancer Prevalence
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Authorities
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. PEST Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. By Disease Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.1.2. Market Attractiveness Index, By Disease Type
  • 9.2. Mild Anemia
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Moderate Anemia
  • 9.4. Severe Anemia

10. By Treatment Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.1.2. Market Attractiveness Index, By Treatment Type
  • 10.2. RBC Transfusions
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Erythropoiesis-stimulating agents (ESAs)
  • 10.4. Iron Supplementation

11. By Drug Type

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.1.2. Market Attractiveness Index, By Drug Type
  • 11.2. Epogen Injection
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Procrit Injection
  • 11.4. Androxy Oral
  • 11.5. Aranesp injection
  • 11.6. Epoetin Alfa Injection
  • 11.7. Others

12. By End User

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.1.2. Market Attractiveness Index, By End User
  • 12.2. Hospitals
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Specialty Clinics
  • 12.4. Ambulatory Surgical Centers
  • 12.5. Cancer Research Centers
  • 12.6. Cancer Rehabilitation Centers

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.7.1. The U.S.
      • 13.2.7.2. Canada
      • 13.2.7.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.7.1. Germany
      • 13.3.7.2. The U.K.
      • 13.3.7.3. France
      • 13.3.7.4. Italy
      • 13.3.7.5. Spain
      • 13.3.7.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.7.1. Brazil
      • 13.4.7.2. Argentina
      • 13.4.7.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.7.1. China
      • 13.5.7.2. India
      • 13.5.7.3. Japan
      • 13.5.7.4. Australia
      • 13.5.7.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Dr. Reddy's Laboratories Ltd.
    • 15.1.1. Company Overview
    • 15.1.2. Disease Type Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Pfizer Inc
  • 15.3. Panacea Biotec Limited
  • 15.4. SBI PHARMACEUTICALS CO., LTD
  • 15.5. Tolero Pharmaceuticals, Inc.
  • 15.6. Vifor Pharma AG
  • 15.7. Therapure Biopharma Inc.
  • 15.8. PharmaEssentia Corp.
  • 15.9. PhytoHealth Corp
  • 15.10. UBI Pharma Inc

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us